ADGI ADAGIO THERAPEUTICS INC

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

WALTHAM, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 14, 2024, at 8:30 a.m. ET to discuss its financial results for the third quarter ended September 30, 2024, and provide recent business highlights. Invivyd reported preliminary third quarter 2024 results via press release on October 29, 2024.

Listeners can register for the webcast via this . Analysts wishing to participate in the question-and-answer session should use this and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company’s investor relations website approximately two hours after the call’s conclusion.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit  to learn more.

Contacts:

Media Relations

(781) 208-1747

Investor Relations

(781) 208-1747



EN
06/11/2024

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Closing of $57.5 Million Public Offering and Full Ex...

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full by the underwriter of its option to purchase an additional 14,423,076 shares of common stock, at a public offering price of $0.52 per share and pre-funded warrants to purchase 21,342,442 shares of its common ...

August 22, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Pricing of $50 Million Public Offering of Common Sto...

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21,342,442 shares of its common stock at a price of $0.5199 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $50.0 million, before dedu...

August 21, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Announces Proposed Public Offering of Common Stock WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Invivyd. The offering is subject to marke...

August 20, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivi...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG variant appears to be driving a growing wave of COVID-19 in AmericaVYD2311 in vitro neutralization data demonstrate similarly consistent and highly potent results against XFGSimilar new, positive in vitro neutralization data for pemivibart and VYD...

August 18, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Reports Second Quarter 2025 Financial Results and Recent Busin...

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-yearInvivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus seasonAnnounced alignment with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody candidate VYD2311 to protect American adults and adolescents from COVID-19Announced attractive safety profile and pharmacokinetics data for VYD23...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch